Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.47 +0.11 (+0.29%)
Streaming Delayed Price Updated: 10:14 AM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 79,603
Open 37.54
Bid (Size) 37.41 (100)
Ask (Size) 37.58 (100)
Prev. Close 37.36
Today's Range 37.08 - 37.59
52wk Range 25.52 - 40.87
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
I Was Shocked to Find This Value-Priced Biotech Growth Stock ↗
But deciding if it's a good buy takes a little more looking. 
Via The Motley Fool
Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill

Performance

YTD
+0.2%
+0.2%
1 Month
-1.2%
-1.2%
3 Month
+24.4%
+24.4%
6 Month
+4.8%
+4.8%
1 Year
-2.0%
-2.0%

More News

Read More
Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy ↗
Via Chartmill
News headline image
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Preview For Harmony Biosciences ↗
Via Benzinga
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
Via Chartmill
News headline image
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
From Beacon Biosignals
Via GlobeNewswire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? ↗
Via Stocktwits
News headline image
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Growth at a Reasonable Price ↗
Via Chartmill
News headline image
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals ↗
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction ↗
Via Chartmill
Topics Earnings
News headline image
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price ↗
Via Chartmill
News headline image
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Undervalued Investment Case ↗
Via Chartmill
News headline image
Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts
Via MarketMinute
Topics Artificial Intelligence Economy Fraud

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?
Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.
What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?
Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?
The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market
What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?
The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 37.47
When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?
The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 01/27/26 10:14 AM ET
What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?
The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 2.14B
How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?
Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.